Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population

Journal of Human Hypertension

Volumn 20, Issue 1, 2006, Pages 45-50

  Dang, A ^a   Zhang, Y ^a   Liu, G ^a   Chen, G ^a   Song, W ^a   Wang, B ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Hypertension; Hyperuricaemia; Irbesartan; Losartan; Uric acid

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; IRBESARTAN; LOSARTAN; PLACEBO; URIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERURICEMIA; HYPERURICOSURIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ASIAN CONTINENTAL ANCESTRY GROUP; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CHINA; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; HYPERURICEMIA; INCIDENCE; LOSARTAN; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; URIC ACID;

EID: 33644966700     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001941     Document Type: Article

References (14)

1. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41(6): 1183-1190.
2. Wurzner G, Gester J-C, Chiolero A, Maillard M, Fallab-Stubi C-L, Brunner HR et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19(10): 1855-1860.
3. Johnson RJ. Uric acid and diet - insights into the epidemic of cardiovascular disease. New Engl J Med 2004; 350: 1071-1073.
4. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, de Faire U et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
5. Choi H. Purine-rich foods, dairy and protein intake, and the risk of gout in men. New Engl J Med 2004; 350: 1093-1103.
6. Weir CJ, Muir SW, Walters MR, Lees KR. Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke. Stroke 2003; 34(8): 1951-1956.
7. Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999; 17(7): 869-872.
8. Fang Qi. Modern Clinical Practice-Uric Acid and Gout. People's Medical Officer Press: Beijing, 1995, pp. 2868-2878.
9. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42(3): 333-335.
10. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7(12): 1035-1040.
11. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2004; 62(6): 572-575.
12. Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002; 41(10): 793-797.
13. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17(7): 1033-1039.
14. Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5(1): 32-40.